Key result
Adjunctive low-dose intracoronary alteplase administered during primary PCI did not reduce microvascular obstruction in patients with ST-segment elevation myocardial infarction.
Why the study?
Does adjunctive low-dose intracoronary alteplase administered during primary PCI reduce microvascular obstruction in patients presenting with ST-segment elevation myocardial infarction (STEMI)?
Does adjunctive low-dose intracoronary alteplase administered during primary PCI reduce microvascular obstruction in patients presenting with ST-segment elevation myocardial infarction (STEMI)?
Adjunctive low-dose intracoronary alteplase during primary PCI does not reduce microvascular obstruction in STEMI patients.
To the Editor The T-TIME trial showed that among patients presenting with ST-segment elevation myocardial infarction (STEMI), adjunctive low-dose intracoronary alteplase administered during primary PCI did not reduce microvascular obstruction.1
No takes yet. Share an insight, caveat, or question.
Mohammad Alkhalil (2019) studied this question. Adjunctive low-dose intracoronary alteplase administered during primary PCI did not reduce microvascular obstruction in patients with ST-segment elevation myocardial infarction.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: